Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

Myelodysplastic Syndromes Clinical Trial

— TMF-Allo  

Official title:

Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04935684
• Other study ID #: PHRC N 2018 BAY
• Secondary ID: 2020-000673-24
• Status: Recruiting
• Phase: Phase 2
• Start date: December 20, 2022
• Est. completion date: December 2027

Study information

• Verified date: October 2022
• Source: University Hospital, Clermont-Ferrand
• Contact: Lise LACLAUTRE
• Phone: +33473754963
• Email: promo_interne_drci[@]chu-clermontferrand.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).

The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.

Description:

The TMF-Allo study is a prospective, open-label, multi-center, parallel, randomized phase II clinical trial comparing a group patients with FMT and a control group of patients without FMT.

The main objective of this study is to assess the effect of allogeneic FMT versus no treatment on Graft-versus-host disease and Relapse-Free Survival (GRFS) at one year in adult patients treating with myelo-ablative allo-HSCT for haematologic malignancy.

The secondary objectives are to evaluate :

• Overall survival, progression-free survival at 1 and 2 years,

• The haematological evolution,

• The evolution of infections,

• The tolerance and safety of the TMF carried out in post-transplant,

• The evolution of the composition and diversity of the microbiota in allograft patients receiving TMF or not.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 2027
• Est. primary completion date: October 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient aged 18 or over

• Men and women

• Patients affiliated with a social-security organization

• Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood)

• Signed and dated informed consent

Exclusion Criteria:

• Status of tumor progression at the time of allo-HSCT

• Inability to understand the protocol (linguistic barrier, cognitive difficulties)

• Medical history of another progressive cancer or occurrence in the 3 previous years (excluding basal cell carcinoma)

• Presence of a simultaneous serious and uncontrolled disease (severe cardiac, renal, hepatic or respiratory failure, severe sepsis)

• Fecal incontinence

• Participation in another clinical trial studying an allograft procedure including the type of graft, the type of immunosuppression, a preventive or a curative treatment of GvHD, or studying the effectiveness of a FMT in another indication.

• Pregnant women

• Patient under guardianship, curatorship or protection of justice

Related Conditions & MeSH terms

• Acute Leukemia in Remission
• Chronic Lymphocytic Leukemia
• Hodgkin Lymphoma
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Lymphoma
• Lymphoma, Non-Hodgkin
• Myelodysplastic Syndromes
• Myeloma
• Myeloproliferative Syndrome
• Syndrome

Intervention

Drug:
• Fecal Microbiota Transplantation
Patients randomized in the "FMT group" will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT. The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes.

Locations

Country	Name	City	State
France	Service d'Hématologie Clinique et Thérapie Cellulaire CHU Amiens Picardie - Site Sud	Amiens
France	Service Maladies du sang CHU Angers	Angers
France	Hématologie clinique CHU Besançon	Besançon
France	Plateforme d'Investigation Clinique / Centre d'Investigation Clinique - Inserm 1405, CHU Gabriel Montpied Clermont-Ferrand	Clermont-Ferrand
France	Service de thérapie Cellulaire et d'Hématologie Clinique Adulte CHU Estaing - Clermont-Ferrand	Clermont-Ferrand
France	Service hématologie CHU Grenoble	Grenoble
France	Service des Maladies du sang Hôpital HURIEZ, CHRU de Lille	Lille
France	Service de thérapie cellulaire et l'hématologie clinique adulte CHU Limoges	Limoges
France	Service d'Hématologie Centre Hospitalier Lyon Sud	Lyon
France	Service d'Hématologie et de Médecine interne Hôpital Brabois CHRU Nancy	Nancy
France	Service d'Hématologie Clinique CHU Nantes	Nantes
France	Service d'hématologie clinique, département de greffe de moelle CHU Nice	Nice
France	Service d'Hématologie Adultes Hôpital Necker	Paris
France	Service d'Hématologie clinique Hôpital Pitié-Salpêtrière	Paris
France	Service d'hématologie greffe Hôpital St Louis	Paris
France	Hématologie clinique et thérapie cellulaire Hôpital Haut-Lévèque	Pessac
France	Service d'hématologie greffe Hôpital St Louis	Poitiers
France	Département d'hématologie CAC Rouen	Rouen
France	Hématologie clinique Institut de Cancérologie de la Loire	Saint-Étienne
France	IUC T - Oncopôle	Toulouse

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Clermont-Ferrand	French Society of Hematology, Ministry of Health, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Graft-versus-host disease and Relapse-Free Survival (GRFS) rate after allogeneic hematopoietic stem cell transplantation	GRFS is a composite endpoint of GvHD-free/relapse-free survival in which events include grade II-IV acute GvHD, moderate and severe chronic GvHD, relapse, or death in the first year post-HSCT. GRFS will be measured at one year after allo-HSCT and compared between both groups of patients.	at Day 360 after allogeneic hematopoietic stem cell transplantation
Secondary	Overall survival	Overall survival is defined as the time period between the date of randomization and the date of death, regardless of its cause.	At Day 360 and Day 720 after allogeneic hematopoietic stem cell transplantation
Secondary	Progression-free survival	Progression-free survival is defined as the time period between the date of randomization and the date of disease relapse or progression or death, regardless of its cause.	At Day 360 and Day 720 after allogeneic hematopoietic stem cell transplantation
Secondary	Haematopoietic reconstitution	Haematopoietic reconstitution is assessed by: 1/ turnaround time of polynuclear neutrophils >0.5.10^9/L (first day within a period of three consecutive days); 2/ spontaneous platelet turnaround time >20.10^9/L (two days with no platelet transfusion within the previous three days); 3/ spontaneous platelet turnaround time >50.10^9/L (two days with no platelet transfusion within the previous three days); 4/ the number of transfusions of red blood cells and platelets between D0 and D100	At the time of haematopoietic reconstitution
Secondary	Engraftment rates	Engraftment rates are evaluated by a chimerism measure (by molecular biology)	At Day 30, Day 60, Day 90, Day 180, Day 360 and Day 720 after allogeneic hematopoietic stem cell transplantationday
Secondary	Cumulative incidence of acute GvHD	Acute GvHD severity is defined according to MAGIC criteria. It will be notified by specifying the location (liver, skin, gut …), the severity score (II to IV), the treatment applied and the efficacy of treatment. GvHD occurrence will be notified every week until D30 (minimum) or until hospital discharge, then monthly until D180 and at D270, D360, D540 and D720.	At Day 360 after allogeneic hematopoietic stem cell transplantation
Secondary	Cumulative incidence of chronic GvHD	Chronic GvHD severity will be defined according to NIHCC criteria. It will be notified by specifying the location (liver, skin, gut …), the severity score (II to IV), the treatment applied and the efficacy of treatment. GvHD occurrence will be notified every week until ungraftment, then monthly until D180 and at D270, D360, D540 and D720.	At Day 720 after allogeneic hematopoietic stem cell transplantation
Secondary	Transplant-Related Mortality	Transplant-related mortality is defined as death due to causes unrelated to the underlying disease.	At Day 180, Day 360 and Day 720 after allogeneic hematopoietic stem cell transplantation
Secondary	Cumulative incidence of infections	Infectious complications will be notified every week up to day 30 (minimum) or until hospital discharge, then every month up to D180 and from D270 to D360, according to the existence of a documented bacteraemia, germ resistance, type and number of days of curative antibiotherapy used; the existence of a documented fungal infection and the type and number of days of curative antifungal treatment; the existence of a documented viral infection and the type and number of days of curative antiviral treatment; the need of an intensive care unit transfer due to an infectious complication.	At Day 360 after allogeneic hematopoietic stem cell transplantation
Secondary	Severe infections description	Severe infections will be defined according to GREFIG score : bactearemia with severe sepsis, complex bactearemia (with deep organ involvement), candidemia (at least one positive blood culture) with sepsis or deep infected site, proven or probable aspergillosis pneumonia, severe varicella-zoster virus infection (involvement of a deep organ or associated coagulopathy), any viral encephalitis, CMV infection with lung or digestive location, Pneumocystis jiroveci pneumonia, toxoplasmosis with involvement of organ or central nervous system, any acute pneumonia with PaO2 less than or equal to 65mmHg, any sepsis requiring transfer to an intensive care unit.	From the day of inclusion to Day 360 after allogeneic hematopoietic stem cell transplantation
Secondary	Impact of Fecal Microbiota Transplantation (FMT) on multi-resistant bacteria, extended-spectrum beta-lactamases and Clostridium difficile infection	Impact of FMT on multi-resistant bacteria, extended-spectrum beta-lactamases and Clostridium difficile infection will be assessed by evaluation of persistence or disappearance of these pathogenic bacteria after FMT.	At Day 360 after allogeneic hematopoietic stem cell transplantation
Secondary	Unexpected event description that could be in relation with FMT of Fecal Microbiota Transplantation (FMT)	Each unexpected event that could be in relation with FMT will be notified: abdominal pain, diarrhea, bacterial translocation or any adverse effect attributed to the enema.	From the day of FMT to Day 360 after allogeneic hematopoietic stem cell transplantation
Secondary	Quality of life assessment	The quality of life will be auto-evaluated by the patients using a validated questionnaire: European Organisation for Research and Treatment of Cancer- Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.	at Day -7, Day 30, Day 90, Day 180, Day 360 and Day 720 after allogeneic hematopoietic stem cell transplantation
Secondary	Analysis the intestinal microbiota in patients	The intestinal microbiota composition and diversity will be assessed by 16S-rRNA sequencing performed prospectively in all patients with FMT and without FMT.	Before the conditioning regimen, before the FMT and at Day 30, Day 90 and Day 360 after white blood cells recovery
Secondary	Analysis the intestinal microbiota in stool donnors	The intestinal microbiota composition and diversity will be assessed by 16S-rRNA sequencing performed prospectively in all stool donnors.	At the time of the first stool donnation between Day 7 to Day 55 after the inclusion
Secondary	Blood collection for a metabolomic study in patients	A blood collection will be set up from blood samples collected on patients from both groups. These samples will be used for a metabolomic study (tryptophan, indoleamine 2,3-dioxygenase, short chain fatty acid, bile acids).	Before the conditioning regimen, before the FMT and at Day 30, Day 90 and Day 360 after white blood cells recovery
Secondary	Blood collection for an analysis of anti-microbiota IgG and IgA in patients	A blood collection will be set up from blood samples collected on patients from both groups. These samples will be used for an analysis of anti-microbiota IgG and IgA.	Before the conditioning regimen, before the FMT and at Day 30, Day 90 and Day 360 after white blood cells recovery
Secondary	Blood collection for a metabolomic study in stool donnors	A blood collection will be set up from blood samples collected on stool donnors. These samples will be used for a metabolomic study (tryptophan, indoleamine 2,3-dioxygenase, short chain fatty acid, bile acids).	At the time of the first stool donnation between Day 7 to Day 55 after the inclusion
Secondary	Blood collection for an analysis of anti-microbiota IgG and IgA in stool donnors	A blood collection will be set up from blood samples collected on stool donnors. These samples will be used for an analysis of anti-microbiota IgG and IgA.	At the time of the first stool donnation between Day 7 to Day 55 after the inclusion
Secondary	Stool collection for an analysis of the virome in patients	A stool collection will be carried out from stool samples collected on patients from both groups.These samples will be used for an analysis of the virome evolution.	Before the conditioning regimen, before the FMT and at Day 30, Day 90 and Day 360 after white blood cells recovery
Secondary	Stool collection for an analysis of the virome in stool donnors	A stool collection will be carried out from stool samples collected on stool donnors.These samples will be used for an analysis of the virome evolution.	At the time of the first stool donnation between Day 7 to Day 55 after the inclusion